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Abstract
The cardiovascular disease (CVD) has been identiﬁed as a leading cause of premature mortality among middle-aged and elderly
individuals globally. Inﬂammation plays an important role in aging and age-related diseases, such as atherosclerosis and CVD. White
blood cell (WBC) count is an inexpensive, simple biomarker of systemic inﬂammations and includes several cell subtype counts, such
as neutrophils, monocytes, lymphocytes, basophils, and eosinophils. However, which component of a WBC count has the ability to
predict CVD remains controversial. The objective of this study was to assess the association betweenmonocyte counts and 10 year-
CVD risk among community-dwelling Korean individuals using the Framingham risk score (FRS). We studied a total of 627
participants aged over 30 years who underwent routine health examinations. The mean age of the study population was 48.1±11.7
years, and 56.9%were male. In the multiple regression analysis, the independent contribution of monocyte count to Framingham 10-
year CVD risk was 0.217±0.092 (P= .018) after adjusting for confounding variables. We found that of the various WBCs, monocyte
count is an independent predictor of CVD risk. Further larger-scale prospective cohort studies are warranted to determine these
associations in the future.
Abbreviations: BMI = body mass index, CVD = cardiovascular disease, FRS = Framingham risk score, SE = standard error,
WBC = white blood cell.
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Inﬂammation is an integrated reaction and a major defensive
mechanism against the disturbance of homeostasis in infectious
and injurious conditions.[1] Recent studies have shown that
inﬂammation plays an important role in disabilities, cancer,
aging, and age-related diseases, such as atherosclerosis and
cardiovascular disease.[2]
Cardiovascular disease (CVD) is a major health problem and
the leading cause of death around the world.[3] It is estimated that
CVD will increase by 10% in the next 20 years.[4] Therefore, it isEditor: Giovanni Tarantino.
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1important to assess preventive measures to minimize CVD risk.
Several markers of inﬂammation have been studied as predictors
of CVD and mortality.[5]
A comprehensive white blood cell (WBC) count includes 5
subtypes: neutrophils, monocytes, lymphocytes, basophils, and
eosinophils. All WBCs play various roles in the inﬂammatory
response and host immunity.[6] Increased total WBC count is
positively associated with CVD, stroke and all-cause mortali-
ty.[7,8] However, it remains unclear which component of the
WBC count has the ability to predict CVD. The main cause of
CVD is atherosclerosis, which is deﬁned as the chronic formation
of plaques in blood vessels.[9] Monocytes are a part of the
mononuclear phagocytic system, with roles in development,
inﬂammation, and host immunity.[10]
The Framingham risk score (FRS) is a simple and feasible
method used for prediction of CVD severity.[11] The objective of
this study was to assess the relationship between monocyte
counts and 10-year CVD risk among community-dwelling
Korean individuals using the FRS.2. Methods
2.1. Study population
We retrospectively reviewed the medical records of 641
sequential subjects older than 30 years of age who voluntarily
received a health examination at the Health Promotion Center at
Gangnam Severance Hospital, Seoul, Korea from January 2007
Kim et al. Medicine (2019) 98:17 Medicinethrough November 2008. Subjects aged 30 years or older were
included, as the FRS can be calculated for this population.[12]
Subjects meeting any of the following criteria were excluded (n=
14): subjects with white blood cell counts of less than 3.0 or more
than 1.1  103cell/mL; subjects with C-reactive protein levels of
more than 10.0mg/L; and subjects with any acute inﬂammatory
disease. Finally, 627 subjects (357 men, 270 women) were
included in our analysis. This study was approved by the
Institutional Review Board of Yonsei University College of
Medicine, Gangnam Severance Hospital (IRB No: 3–2018–
0266). All subjects provided informed consent.2.2. Data collection
The examinations were performed by medical staff according to
standard procedures. Participants were asked about lifestyle
behaviors, including cigarette smoking, alcohol consumption, and
physical activity. They were also questioned about whether they
were currently undergoing treatments for any disease and, if so,
they were asked for the date of diagnosis and a list of current
medications. Trained staff reviewed the completed questionnaires
and entered the responses into a database. Participants were
categorized as non-smokers, ex-smokers, or current smokers.
Subjects were also classiﬁed as non-drinkers/abstainers (<140g/
week) or current drinkers (≥140g/week). Height and body weight
were measured to the nearest 0.1cm and 0.1kg in light indoor
clothing andwithout shoes. Bodymass index (BMI)was calculated
as the ratio of weight (kg)/height (m2). Blood pressure was
measured with the participant in a sitting position after 5 minutes
of rest using an automated device (TM-2665P, A&D Co., LTD.,
Tokyo, Japan). Hypertension was deﬁned as a history of taking
hypertension medication, systolic blood pressure ≥140mmHg, or
diastolic blood pressure ≥90 mmHg. Diabetes was deﬁned as a
history of taking diabetes medication or a fasting plasma glucose
level ≥126mg/dL. After a 12-hour overnight fast, blood samples
were taken fromanantecubital vein. Tubes containing EDTAwere
used for the whole blood count. WBCs were quantiﬁed by an
automated blood cell counter (ADVIA 120, Bayer, NY) within 1
hour of blood sampling. Fasting plasma glucose, total cholesterol,
triglycerides, high-density lipoprotein (HDL)cholesterol, aspartate
aminotransferase, alanine aminotransferase, and uric acid levels
were measured using a Hitachi 7600–110 Chemistry system
Autoanalyzer (Hitachi, Tokyo, Japan).
The modiﬁed National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III) was used to deﬁne metabolic
syndrome. Because waist circumference was not measured, we
deﬁned obesity as BMI ≥ 25kg/m2, as suggested by the position
statement of the American College of Endocrinology.[13] There-
fore, metabolic syndrome was deﬁned by the presence of three or
more of the following risk factors: obesity with BMI ≥25.0kg/m2;
elevated systolic blood pressure ≥130 mmHg, elevated diastolic
blood pressure ≥85 mmHg, or use of an anti-hypertensive
medication; high fasting plasma glucose ≥100mg/dL or use of an
anti-diabetes medication; high triglycerides ≥150mg/dL; and low
HDL cholesterol <40mg/dL for men and <50mg/dL for women.2.3. Deﬁnition of the Framingham risk score (FRS)
The FRS, a widely-accepted tool, is derived from the Framingham
Heart Study and used to predict the risk of coronary disease, such
as angina, myocardial infarction, cardiovascular death over a 10-
year period. This risk assessment is a sex-speciﬁc method2determined with the following set of variables: sex (male/female),
age (years), systolic blood pressure (mmHg), treatment for
hypertension (yes/no), diabetes status (yes/no), current smoker
(yes/no), total cholesterol (mg/dL), and HDL cholesterol (mg/
dL).[14] The FRS is composed of both modiﬁable (smoking,
systolic blood pressure, use of antihypertensive medication,
dyslipidemia, diabetes status) and not-modiﬁable (age, sex) risk
factors. Individuals’ scores, representative of their 10-year risk of
developing CVD and calculated based on their total points, are
typically categorized as low (FRS < 10%), intermediate (FRS=
10–20%), or high (FRS > 20%).[15]
The FRS is a consistent, precise risk score that has been
validated in large population studies.[16] In addition, recent
studies have mentioned that the FRS is a reasonable alternative
for use in multiethnic groups.[17] This risk score can be useful for
both patient education and clinicians deciding whether lifestyle
modiﬁcation or medical treatment is warranted.[18] The FRS was
calculated using a computer program.[19]2.4. Statistical analysis
All analyses were conducted using SAS statistical software,
version 9.4 (SAS Institute Inc, Cary, NC). The demographic and
biochemical characteristics of the study population were
analyzed using independent 2-sample t tests for continuous
variables and the chi-squared tests for categorical variables. A
multiple regression analysis was performed in order to determine
whether monocyte count is an independent determinant for an
increased Framingham 10-year CVD risk after adjusting for other
confounding variables. All statistical tests were 2-sided, and
statistical signiﬁcance was determined at P< .05.3. Results
Table 1 shows the clinical and chemical characteristics of the 357
men and 270 women. The mean age of the study population was
48.1±11.7 years, and the mean BMI was 23.8±2.9kg/m2.
Systolic blood pressure, diastolic blood pressure, fasting plasma
glucose and triglyceride levels, Framingham 10-year CVD risk,
WBC count and monocyte count were all higher in men
compared to women.
Table 2 shows the correlation between Framingham 10-year
CVD risk and other indicators for CVD risk. In the Pearson
correlation analysis, Framingham 10-year CVD risk was
correlated with age, BMI, systolic blood pressure, fasting plasma
glucose, plasma triglyceride level, HDL cholesterol, monocyte
count, and eosinophil count.
Table 3 shows the independent contribution of WBC subtypes
to Framingham 10-year CVD risk. In multiple regression model
1, the b for Framingham 10-year CVD risk was 0.266±0.116
(P= .022) with monocyte count increment after adjusting for age,
sex, BMI, and WBC count. We also assessed the association
between Framingham 10-year CVD risk and monocyte count
after additional adjustment for smoking status, alcohol con-
sumption, regular exercise, systolic blood pressure, fasting
plasma glucose, triglyceride, HDL cholesterol, alanine amino-
transferase, creatinine, C-reactive protein, hypertension medica-
tion, diabetes medication, and dyslipidemia medication. Finally,
we performed multiple logistic regression analysis in the same
way after additional adjustment for metabolic syndrome. The
associations were similar after using models 2, 3, and 4 (Table 3).
The b for Framingham 10-year CVD risk was 0.278±0.097
Table 1
Clinical and biochemical characteristics of the study population.
Total (n=627) Men (n=357) Women (n=270) P value
Age, years 48.1±11.7 48.5±10.4 47.7±13.3 .421
Body mass index, kg/m2 23.8±2.9 24.6±2.6 22.8±2.9 <.001
Current smoker, % 22.5 37.8 2.2 <.001
Alcohol consumption,
∗
% 71.1 82.1 56.7 <.001
Regular exercise,† % 58.4 51.5 67.4 <.001
Systolic blood pressure, mmHg 119.8±15.2 123.2±13.9 115.4±15.9 <.001
Diastolic blood pressure, mmHg 73.3±11.9 75.9±10.9 69.9±12.3 <.001
Fasting plasma glucose, mg/dL 96.8±20.4 100.8±24.9 91.5±10.2 <.001
Triglyceride, mg/dL 113.4±92.5 131.0±91.3 90.2±89.0 <.001
HDL cholesterol, mg/dL 47.6±12.4 43.9±10.7 52.5±13.0 <.001
Aspartate aminotransferase, IU 22.9±4.9 24.2±4.7 21.2±4.5 <.001
Alanine aminotransferase, IU 21.4±7.7 24.4±7.2 17.4±6.3 <.001
Creatinine, mg/dL 0.8±0.2 0.9±0.1 0.7±0.1 <.001
C-reactive protein, mg/L 0.9±1.3 1.1±1.5 0.7±1.1 <.001
Hypertension medication, % 12.6 14.3 10.4 .143
Diabetes medication, % 4.8 5.6 3.7 .270
Dyslipidemia medication, % 4.9 4.8 5.2 .808
Metabolic syndrome, % 27.8 31.1 23.3 .031
Framingham 10-year CVD risk, % 5.7±6.4 8.1±6.8 2.5±3.8 <.001
White blood cells, x 103 cell/mL 5.5±1.3 5.7±1.4 5.3±1.2 <.001
Neutrophils, % 54.2±7.9 53.7±7.5 54.8±8.4 .067
Lymphocytes, % 36.4±7.2 36.4±6.7 36.4±7.7 .931
Monocytes, % 6.2±1.6 6.4±1.6 6.0±1.7 .011
Eosinophils, % 3.0±2.3 3.4±2.5 2.6±1.9 <.001
Basophils, % 1.1±0.2 1.1±0.2 1.1±0.3 .635
Data are expressed as mean (standard deviation) or percentage.
∗
Alcohol consumption is deﬁned as ≥140 g/week.
† Regular exercise is deﬁned as ≥twice/week.
Kim et al. Medicine (2019) 98:17 www.md-journal.com(P= .004), 0.217±0.092 (P= .018), 0.223±0.096 (P= .020) in
models 2, 3, and 4, respectively.4. Discussion
For community-dwelling individuals without clinical acute
inﬂammatory disorders, our study showed a positive associationTable 2
Correlation between Framingham 10-year CVD risk and indicators
for cardiovascular risk.
Variables r
∗
P value†
Age, years 0.526 <.001
Body mass index, kg/m2 0.333 <.001
Systolic blood pressure, mmHg 0.390 <.001
Diastolic blood pressure, mmHg 0.319 <.001
Fasting plasma glucose, mg/dL 0.401 <.001
Triglyceride, mg/dL 0.268 <.001
HDL cholesterol, mg/dL 0.308 <.001
Aspartate aminotransferase, IU 0.284 <.001
Alanine aminotransferase, IU 0.326 <.001
Creatinine, mg/dL 0.349 <.001
C-reactive protein, mg/L 0.236 <.001
White blood cells, 103 cell/mL 0.199 <.001
Neutrophils, % 0.030 .442
Lymphocytes, % 0.032 .413
Monocytes, % 0.121 .002
Eosinophils, % 0.094 .021
Basophils, % 0.015 .832
∗
Correlation coefﬁcient.
† P value on Pearson correlation analysis.
3ofmonocyte count with 10-year CVD risk estimates, independent
of classical cardiovascular risk factors. These effects remained
after adjusting for the presence of vascular function-modifying
drugs such as anti-hypertensive drugs, lipid lowering agents, and
anti-diabetic drugs.
We aimed to identify the association between components of
WBC counts with CVD risk in routine clinical practice. This is the
ﬁrst population-based retrospective study to assess the associa-
tion of all elements of WBC counts and Framingham risk score.
Inﬂammation is a main process in the development of CVD.[20]
Atherosclerosis reﬂects the pathological substrate of CVD.[21]
Many mediators are involved in the regulation of interactive
inﬂammation in atherosclerosis.[22,23] Atherosclerotic plaque
initiation, progression, vulnerability, and thrombosis formation
are consecutive phenomena involving the interaction of lip-
oproteins, vascular wall components, blood cells, and the
immune system,[24] which are more clearly evident with blood
viscosity, especially in early atherosclerosis.[25] WBC count is
widely used as an inexpensive, simple biomarker of systemic
inﬂammation. It is an integrated indicator including several WBC
subtypes, such as neutrophils, monocytes, lymphocytes, baso-
phils, and eosinophils. Broadly, WBC count indicates the level of
host response to stresses, the index of acute or chronic
inﬂammatory processes.[26] Therefore, WBC count has been
associated with many long-term health risks, and has been shown
to predict risk for all-cause mortality, cancer, and cardiovascular
disease.[27,8] In this study, monocyte count was associated with
an increased FRS used to predict the risk of CVD over a 10-year
period. Actually, a recent prospective study that examined 1000
Korean people over 6 years demonstrated that the hazard ratio
for CVD mortality was 2.81 in the 3rd tertile of monocyte count
Table 3
Multiple regression analysis showing the independent contribution of WBC subtypes to Framingham 10-year CVD risk.
Model 1
∗
Model 2† Model 3‡ Model 4x
b±SE P value b±SE P value b±SE P value b±SE P value
White blood cells 0.306±0.146 .036 0.221±0.132 .095 0.167±0.123 .176 0.237±0.127 .062
Neutrophils 0.003±0.025 .903 0.015±0.021 .478 0.015±0.020 .457 0.012±0.021 .581
Lymphocytes 0.017±0.028 .531 0.040±0.023 .092 0.033±0.022 .131 0.027±0.023 .244
Monocytes 0.266±0.116 .022 0.278±0.097 .004 0.217±0.092 .018 0.223±0.096 .020
Eosinophils 0.001±0.086 .985 0.041±0.075 .579 0.027±0.070 .694 0.007±0.074 .928
Basophils 0.907±1.413 .521 0.126±1.115 .910 0.242±1.054 .818 0.280±1.100 .799
∗
Model 1: adjusted for age, sex, body mass index, and white blood cell count.
†Model 2: adjusted for age, sex, body mass index, white blood cell count, smoking status, alcohol consumption, regular exercise, systolic blood pressure, and fasting plasma glucose, triglyceride, HDL cholesterol,
alanine aminotransferase, creatinine, and C-reactive protein levels.
‡Model 3: adjusted for age, sex, body mass index, white blood cell count, smoking status, alcohol consumption, regular exercise, systolic blood pressure, fasting plasma glucose, triglyceride, HDL cholesterol,
alanine aminotransferase, creatinine, C-reactive protein levels, hypertension medication, diabetes medication, and dyslipidemia medication.
xModel 4: adjusted for age, sex, body mass index, white blood cell count, smoking status, alcohol consumption, regular exercise, alanine aminotransferase, creatinine, C-reactive protein levels, hypertension
medication, diabetes medication, dyslipidemia medication, and metabolic syndrome.
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count has been demonstrated to have an increased coronary
artery plaque formation in subclinical stage.
The signiﬁcance of our study is backed up by the fact that
monocyte count is a potentially better predictor of cardiovascular
disease risk than total WBC alone. Monocytes are released from
the bone marrow into the blood vessels. It is a part of the
mononuclear phagocyte system, with roles in inﬂammation and
host immunity. Circulating monocytes adhere to the activated
endothelium, inﬁltrate the vessel wall, and are exposed to growth
factors, inducing their differentiation to macrophages, which
ingest lipids and become foam cells.[29] Atherosclerosis is initiated
when the endothelium is damaged by metabolic syndrome,
hypertension, diabetes, dyslipidemia, and requires subendothelial
accumulation of low-density lipoprotein (LDL) cholesterol.[30,31]
Under metabolic stress, LDL cholesterol becomes oxidized, and
oxidized LDL cholesterol worsen endothelial cell dysfunction.[32]
Activated endothelial cells express adhesion molecules and
increase certain chemoattractants, such as interleukin-8 (IL-8)
and monocyte chemoattractant protein-1 (MCP-1). This affects
the recruitment of monocytes into the vascular endothelium.[33]
The relationship between circulating monocytes and the novel
atherosclerotic plaque is signiﬁcant.[34] The activation of
monocytes and their differentiation into lipid-laden macro-
phages, known as foam cells, are essential reactions in the
formation of atherosclerotic lesions. Atherosclerosis is a
progressive disease with a chronic asymptomatic phase charac-
terized by inﬂammation and lipid accumulation in the vessel wall,
leading to plaque build-up. Therefore, most people with elevated
CVD risk are unaware of their critical condition.[35] Macro-
phages, descended from monocytes, are the immune cells that
regulate development, and function in host immunity and
inﬂammation. Macrophages exist in all tissues, and phagocytize
cellular debris and pathogens.Macrophages present antigens to T
cells and produce cytokines to modify cells when tissues are
injured. Macrophages are highly plastic and dynamic.[36] The
heart and blood vessels contain a number of macrophages.
Macrophages capture about 8% of noncardiomyocytes in the
heart. This percentage can signiﬁcantly alter the underlying
conditions of CVD.[37] Also, metabolic syndrome, which is a
combination of cardiometabolic risk factors, is generally linked
to increased visceral adiposity, which can be implicated in non-
alcoholic fatty liver disease and subsequently early atherosclero-
sis.[38] Our study showed the overall prevalence of metabolic4syndromewas 31.1% inmen and 23.3% inwomen and a positive
association between monocyte count and 10-year CVD risk
estimates remained after additional adjusting for the presence of
metabolic syndrome.
Our study has several limitations. First, since all study subjects
were volunteers who had visited a single hospital for a physical
evaluation, some having co-morbidity condition, the way in
which the study population was enrolled may have introduced
selection bias and may have failed to gather a representative
sample of the general Korean population, albeit performing after
excluding subjects with any acute inﬂammatory disease and
adjusting for the presence of vascular function-modifying drugs.
Second, this is a cross-sectional studywithout control population,
so additional prospective longitudinal studies are needed to
investigate the cause and effect between monocytes and the
development of CVD over a longer time period.
In conclusion, taking into account the role of monocytes in
atherosclerosis, our results suggest that the early detection of
increased monocyte counts may be important for the assessment
of cardiovascular health management. Further larger-scale
prospective cohort studies are warranted to determine these
associations in the future.Author contributions
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